한글목차

클라불란산 계열 원료의약품(API) 세계 시장은 2024년 3억 9,421만 달러로 평가되었고, 예측 기간 동안 6.87%의 연평균 복합 성장률(CAGR)로 2030년에는 5억 8,870만 달러에 달할 것으로 예상됩니다.

세계 클라불란산 계열 원료의약품(API) 시장은 주로 병용 항생제에 대한 수요 증가에 의해 주도되고 있습니다. 클라불란산은 박테리아가 항생제에 저항하기 위해 생산하는 β-락타마제 효소를 억제하여 페니실린계 항생제의 효과를 높이는 데 사용됩니다. 내성균 증가와 광범위 항생제에 대한 수요 증가는 시장 성장을 가속하는 중요한 요인입니다. 신흥 시장에서의 의료 접근성 확대와 폐렴, 요로 감염, 호흡기 감염과 같은 감염성 질환의 유병률 증가는 클루란산 기반 의약품에 대한 수요 증가에 기여하고 있습니다. 새로운 제형에 대한 연구가 진행되고 있고, 인간과 동물용 의약품 모두에서 병용약물의 사용이 증가함에 따라 시장 성장세를 유지할 것으로 예상됩니다.

시장 성장 촉진요인

항생제 내성 증가와 효과적인 치료법의 필요성이 대두되고 있습니다.

주요 시장 이슈

생산 비용 상승과 공급망 혼란

주요 시장 동향

수의학 분야 수요 증가

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 고객의 소리

제5장 세계의 클라불란산 계열 원료의약품(API) 시장 전망

• 시장 규모와 예측
  • 금액별
• 시장 점유율과 예측
  • 유형별(Amoxicillin & Potassium Clavulanate, Potassium Clavulanate with Avicel, Potassium Clavulanate with Silicon Dioxide)
  • 용도별(경구약, 주사약)
  • 지역별
  • 기업별(2024년)
• 시장 맵

제6장 북미의 클라불란산 계열 원료의약품(API) 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 북미 : 국가별 분석
  • 캐나다
  • 멕시코

제7장 유럽의 클라불란산 계열 원료의약품(API) 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 유럽 : 국가별 분석
  • 영국
  • 이탈리아
  • 프랑스
  • 스페인

제8장 아시아태평양의 클라불란산 계열 원료의약품(API) 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 아시아태평양 : 국가별 분석
  • 인도
  • 일본
  • 한국
  • 호주

제9장 남미의 클라불란산 계열 원료의약품(API) 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 남미 : 국가별 분석
  • 아르헨티나
  • 콜롬비아

제10장 중동 및 아프리카의 클라불란산 계열 원료의약품(API) 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 중동 및 아프리카 : 국가별 분석
  • 사우디아라비아
  • 아랍에미리트(UAE)

제11장 시장 역학

• 성장 촉진요인
• 과제

제12장 시장 동향과 발전

• 인수합병(M&A)(있는 경우)
• 제품 발매(있는 경우)
• 최근 동향

제13장 Porter의 Five Forces 분석

• 업계내 경쟁
• 신규 참여 가능성
• 공급업체의 힘
• 고객의 힘
• 대체품의 위협

제14장 경쟁 구도

• Apotex Inc.
• Centrient Holding B.V.
• CKD BiO Corp.
• Fidia Farmaceutici S.p.A.
• GlaxoSmithKline Plc
• Hikma Pharmaceuticals Plc
• Sandoz Group AG
• Novopharm Formulations Private Limited
• Rochem International Inc.
• Senova Technology Co. Ltd.

제15장 전략적 제안

제16장 리서치사에 대해 & 면책사항

영문목차

Global Clavulanic Acid Series API Market was valued at USD 394.21 Million in 2024 and is expected to reach USD 588.70 Million by 2030 with a CAGR of 6.87% during the forecast period. The global clavulanic acid series API market is primarily driven by the increasing demand for combination antibiotics. Clavulanic acid is used to enhance the effectiveness of penicillin-based antibiotics by inhibiting beta-lactamase enzymes that bacteria produce to resist antibiotics. The rise in bacterial resistance and the growing need for broad-spectrum antibiotics are significant factors fueling market growth. The expansion of healthcare access in emerging markets and the increasing prevalence of infections such as pneumonia, urinary tract infections, and respiratory infections further contribute to the demand for clavulanic acid-based medicines. The ongoing research into new drug formulations and the increasing use of combination drugs in both human and veterinary medicine are expected to sustain the market's growth.

Key Market Drivers

Rising Antibiotic Resistance and Need for Effective Treatments

Antibiotic resistance remains one of the most pressing challenges facing global healthcare today. Bacteria have evolved numerous mechanisms to resist antibiotics, rendering many traditional treatments ineffective. This growing problem is particularly severe in healthcare settings, where infections like pneumonia, bloodstream infections, and urinary tract infections are becoming harder to treat due to resistant strains. The rise of multi-drug-resistant (MDR) and extensively drug-resistant (XDR) bacteria highlights the urgent need for effective solutions. Clavulanic acid, when combined with beta-lactam antibiotics such as amoxicillin, becomes an essential tool in the fight against these resistant pathogens. In January 2021, the central government revealed the names of the first three companies eligible for financial support under the production-linked incentive (PLI) scheme aimed at promoting domestic manufacturing of critical key starting materials (KSMs), drug intermediates, and active pharmaceutical ingredients (APIs). The companies include Aurobindo Pharma, based in Hyderabad, Kinvan Pvt Ltd from Mumbai, and the public sector firm Karnataka Antibiotics and Pharmaceuticals.

Key Market Challenges

Rising Production Costs and Supply Chain Disruptions

The production of clavulanic acid is a complex process that requires specialized fermentation and synthesis techniques. The production of high-quality clavulanic acid APIs involves significant raw material costs and capital investment in specialized equipment. Manufacturers often face fluctuating prices for key raw materials such as fermentation substrates and chemicals, which can result in increased production costs. These cost pressures can affect the final pricing of clavulanic acid-based antibiotics, especially in price-sensitive markets where affordability is a key concern.

The global supply chain for pharmaceutical ingredients can be subject to disruptions, whether from natural disasters, geopolitical factors, or trade restrictions. The COVID-19 pandemic, for example, highlighted the vulnerabilities in the global pharmaceutical supply chain, as manufacturers faced difficulties sourcing raw materials, facing shipping delays, and experiencing interruptions in production. Such disruptions can lead to delays in API supply, reduced availability of key products, and higher production costs, which could impede the growth of the clavulanic acid market.

Key Market Trends

Increased Demand from the Veterinary Sector

An emerging driver for the Global Clavulanic Acid Series API Market is the increasing demand for clavulanic acid-based antibiotics in the veterinary sector. Animals, especially livestock such as poultry, cattle, and pigs, are often treated with antibiotics to prevent infections and promote growth. The rise in animal infections caused by bacterial pathogens resistant to conventional antibiotics has spurred the demand for combination therapies that include clavulanic acid. These antibiotics are effective in treating a wide variety of bacterial infections in animals, including respiratory and gastrointestinal infections.

The growing global demand for animal protein, especially in emerging markets, has led to an increase in livestock farming. Consequently, veterinary antibiotics that combine clavulanic acid are becoming more widely used to control bacterial infections in animals. The increasing regulations and focus on animal welfare also ensure that only effective antibiotics, such as those containing clavulanic acid, are used in livestock, driving demand in the veterinary market and thus contributing to the overall growth of the clavulanic acid API market.

Key Market Players

• Apotex Inc.
• Centrient Holding B.V.
• CKD BiO Corp.
• Fidia Farmaceutici S.p.A.
• GlaxoSmithKline Plc
• Hikma Pharmaceuticals Plc
• Sandoz Group AG
• Novopharm Formulations Private Limited
• Rochem International Inc.
• Senova Technology Co. Ltd.

Report Scope:

In this report, the Global Clavulanic Acid Series API Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Clavulanic Acid Series API Market, By Type:

• Potassium Clavulanate
• Amoxicillin & Potassium Clavulanate
• Potassium Clavulanate with Avicel
• Potassium Clavulanate with Silicon Dioxide

Clavulanic Acid Series API Market, By Application:

• Oral Medications
• Injectable Medications

Clavulanic Acid Series API Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Clavulanic Acid Series API Market.

Available Customizations:

Global Clavulanic Acid Series API market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validations
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Clavulanic Acid Series API Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Potassium Clavulanate, Amoxicillin & Potassium Clavulanate, Potassium Clavulanate with Avicel, Potassium Clavulanate with Silicon Dioxide)
  • 5.2.2. By Application (Oral Medications and Injectable Medications)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Clavulanic Acid Series API Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Application
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Clavulanic Acid Series API Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Application
  • 6.3.2. Canada Clavulanic Acid Series API Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Application
  • 6.3.3. Mexico Clavulanic Acid Series API Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Application

7. Europe Clavulanic Acid Series API Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Application
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Clavulanic Acid Series API Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Application
  • 7.3.2. United Kingdom Clavulanic Acid Series API Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Application
  • 7.3.3. Italy Clavulanic Acid Series API Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Application
  • 7.3.4. France Clavulanic Acid Series API Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Application
  • 7.3.5. Spain Clavulanic Acid Series API Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Application

8. Asia-Pacific Clavulanic Acid Series API Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Application
  • 8.2.3. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Clavulanic Acid Series API Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Application
  • 8.3.2. India Clavulanic Acid Series API Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Application
  • 8.3.3. Japan Clavulanic Acid Series API Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Application
  • 8.3.4. South Korea Clavulanic Acid Series API Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Application
  • 8.3.5. Australia Clavulanic Acid Series API Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Application

9. South America Clavulanic Acid Series API Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Application
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Clavulanic Acid Series API Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Application
  • 9.3.2. Argentina Clavulanic Acid Series API Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Application
  • 9.3.3. Colombia Clavulanic Acid Series API Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Application

10. Middle East and Africa Clavulanic Acid Series API Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Application
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Clavulanic Acid Series API Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Application
  • 10.3.2. Saudi Arabia Clavulanic Acid Series API Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Application
  • 10.3.3. UAE Clavulanic Acid Series API Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. Apotex Inc.
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. Centrient Holding B.V.
• 14.3. CKD BiO Corp.
• 14.4. Fidia Farmaceutici S.p.A.
• 14.5. GlaxoSmithKline Plc
• 14.6. Hikma Pharmaceuticals Plc
• 14.7. Sandoz Group AG
• 14.8. Novopharm Formulations Private Limited
• 14.9. Rochem International Inc.
• 14.10. Senova Technology Co. Ltd.

15. Strategic Recommendations

16. About Us & Disclaimer